Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050. We got a glimpse into Eli ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Eli Lilly is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk being its biggest challenger. Over the past six months, Eli Lilly has earned significant wins ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, ...

The pharmaceutical giant has been racing against rivals such as Eli Lilly to dominate the highly lucrative weight-loss space. Novo Nordisk CEO Lars Fruergaard Jorgensen speaks during a TV ...

CHGCY believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s LLY oral obesity pill, orforglipron. Roche Holdings AG RHHBY is a major shareholder of Chugai, a Japanese ...